New editorial on HER2 in breast cancer discusses prognosis, prediction, and targeted therapies like trastuzumab.
- A new editorial paper titled "HER2-low and HER2-zero in breast cancer between prognosis, prediction and entity" has been published in Oncotarget.
- Researchers discuss the role of HER2 in breast cancer, which is a well-established prognostic and predictive factor associated with a poor prognosis but potential for improved survival with targeted therapies.
- The American Society of Clinical Oncology defines HER2-positivity based on specific criteria, but a majority of breast tumors are considered HER2-negative under these guidelines.
- Results of randomized trials with trastuzumab-based antibody-drug conjugates challenge the previous belief that HER2-negative tumors do not benefit from trastuzumab therapy.
- The editorial provides insights into the evolving understanding of HER2 status in breast cancer and its implications for treatment strategies.
Source link
Oncology, Pathology & Lab Medicine